Intravenous Iron Drugs Global Market Report 2025

Description

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, particularly in patients who cannot tolerate or do not respond well to oral iron supplements. These drugs quickly elevate iron levels, support hemoglobin production, and enhance oxygen transport in the body, helping to relieve symptoms such as fatigue and weakness.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary product types of intravenous iron drugs include iron dextran, iron sucrose, ferric carboxymaltose, and other formulations. Iron dextran is an injectable iron therapy used for rapid iron replenishment in patients with severe deficiencies where oral iron is ineffective or poorly tolerated. These drugs are used to treat various conditions, including chronic kidney disease, inflammatory bowel disease, cancer, and other disorders. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The intravenous iron drugs market research report is one of a series of new reports from The Business Research Company that provides intravenous iron drugs market statistics, including the intravenous iron drugs global market size, regional shares, competitors with the intravenous iron drugs market share, detailed intravenous iron drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the intravenous iron drugs. This intravenous iron drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The intravenous iron drugs market size has grown rapidly in recent years. It will grow from $3.44 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth during the historic period can be attributed to the increasing prevalence of iron deficiency anemia, a rise in chronic diseases, growing healthcare expenditure, an aging population, and the rising incidence of target illnesses requiring intravenous iron therapy.

The intravenous iron drugs market size is expected to see rapid growth in the next few years. It will grow to $5.86 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth during the forecast period can be attributed to supportive government initiatives, ongoing research and development in the field of intravenous (IV) iron drugs, increasing demand for IV iron therapies, a rising number of R&D activities, and improvements in drug administration and formulation. Key trends expected in the forecast period include the emergence of advanced intravenous iron therapies, significant advancements in drug development, a shift toward more convenient IV iron treatment options, strategic collaborations, partnerships, and acquisitions, as well as innovations in novel drug delivery systems.

The growing incidence of chronic kidney disease (CKD) is expected to drive significant growth in the intravenous iron drugs market. CKD is a progressive condition characterized by the gradual decline of kidney function, impairing the body's ability to filter waste and excess fluids from the blood. This rising trend is largely attributed to the increasing prevalence of diabetes and hypertension two major contributors to kidney damage. Intravenous iron drugs play a crucial role in managing CKD-related anemia by restoring iron levels, improving hemoglobin concentrations, and enhancing oxygen delivery in the body. These benefits reduce reliance on erythropoiesis-stimulating agents and support better patient outcomes. For example, in June 2024, the Australian Institute of Health and Welfare reported that CKD-related mortality increased by 4.2% in 2021 and by 6.2% in 2022. In 2022 alone, CKD accounted for approximately 22,000 deaths in Australia, representing 11% of total fatalities. As a result, the growing burden of CKD is accelerating the demand for intravenous iron therapies.

Leading players in the intravenous iron drugs market are prioritizing the development of advanced intravenous (IV) iron replacement therapies to enhance safety, efficacy, and patient experiences. IV iron replacement therapy involves delivering iron directly into the bloodstream, making it an effective treatment for iron deficiency and anemia, particularly in patients who are unable to tolerate or absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited a Japan-based pharmaceutical innovator announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adults with New York Heart Association class II/III heart failure. This approval supports the use of Injectafer to improve exercise capacity and addresses iron deficiency in a key patient population. Known for its rapid iron repletion capabilities, Injectafer offers a valuable alternative to oral therapies, enhancing treatment adherence and outcomes.

In August 2022, CSL Limited, an Australia-based biotechnology company known for its focus on plasma therapies and specialty pharmaceuticals, acquired Vifor Pharma for an undisclosed sum. This strategic acquisition enhances CSL's capabilities in nephrology and iron deficiency management, significantly strengthening its portfolio in renal and cardiovascular care. Vifor Pharma AG, headquartered in Switzerland, is recognized globally for its expertise in iron deficiency treatments and nephrology-focused pharmaceuticals.

Major players in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy's Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the intravenous iron drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intravenous iron drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intravenous iron drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravenous iron drugs market consists of sales of ferric gluconate, ferumoxytol, ferric derisomaltose, and sodium ferric gluconate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intravenous Iron Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intravenous iron drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intravenous iron drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous iron drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose; Other Product Types
2) By Indication: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Diseases
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran; High Molecular Weight Iron Dextran
2) By Iron Sucrose: Standard Iron Sucrose Injection; Iron Sucrose Complex
3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose; Multiple-Dose Ferric Carboxymaltose
4) By Other Product Types: Ferumoxytol; Ferric Derisomaltose; Sodium Ferric Gluconate
Companies Mentioned: AbbVie Inc.; Sanofi S.A.; Amgen Inc.; Fresenius SE & Co. KGaA; Teva Pharmaceutical Industries Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34882

1. Executive Summary

2. Intravenous Iron Drugs Market Characteristics

3. Intravenous Iron Drugs Market Trends And Strategies

4. Intravenous Iron Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Intravenous Iron Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Intravenous Iron Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Intravenous Iron Drugs Market Growth Rate Analysis
5.4. Global Intravenous Iron Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Intravenous Iron Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Intravenous Iron Drugs Total Addressable Market (TAM)

6. Intravenous Iron Drugs Market Segmentation

6.1. Global Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Other Product Types
6.2. Global Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Other Diseases
6.3. Global Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Iron Dextran, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low Molecular Weight Iron Dextran
High Molecular Weight Iron Dextran
6.5. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Iron Sucrose, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard Iron Sucrose Injection
Iron Sucrose Complex
6.6. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Ferric Carboxymaltose, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Dose Ferric Carboxymaltose
Multiple-Dose Ferric Carboxymaltose
6.7. Global Intravenous Iron Drugs Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ferumoxytol
Ferric Derisomaltose
Sodium Ferric Gluconate

7. Intravenous Iron Drugs Market Regional And Country Analysis

7.1. Global Intravenous Iron Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Intravenous Iron Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intravenous Iron Drugs Market

8.1. Asia-Pacific Intravenous Iron Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intravenous Iron Drugs Market

9.1. China Intravenous Iron Drugs Market Overview
9.2. China Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intravenous Iron Drugs Market

10.1. India Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intravenous Iron Drugs Market

11.1. Japan Intravenous Iron Drugs Market Overview
11.2. Japan Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intravenous Iron Drugs Market

12.1. Australia Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intravenous Iron Drugs Market

13.1. Indonesia Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intravenous Iron Drugs Market

14.1. South Korea Intravenous Iron Drugs Market Overview
14.2. South Korea Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intravenous Iron Drugs Market

15.1. Western Europe Intravenous Iron Drugs Market Overview
15.2. Western Europe Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intravenous Iron Drugs Market

16.1. UK Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intravenous Iron Drugs Market

17.1. Germany Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intravenous Iron Drugs Market

18.1. France Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intravenous Iron Drugs Market

19.1. Italy Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intravenous Iron Drugs Market

20.1. Spain Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intravenous Iron Drugs Market

21.1. Eastern Europe Intravenous Iron Drugs Market Overview
21.2. Eastern Europe Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intravenous Iron Drugs Market

22.1. Russia Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intravenous Iron Drugs Market

23.1. North America Intravenous Iron Drugs Market Overview
23.2. North America Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intravenous Iron Drugs Market

24.1. USA Intravenous Iron Drugs Market Overview
24.2. USA Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intravenous Iron Drugs Market

25.1. Canada Intravenous Iron Drugs Market Overview
25.2. Canada Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intravenous Iron Drugs Market

26.1. South America Intravenous Iron Drugs Market Overview
26.2. South America Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intravenous Iron Drugs Market

27.1. Brazil Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intravenous Iron Drugs Market

28.1. Middle East Intravenous Iron Drugs Market Overview
28.2. Middle East Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intravenous Iron Drugs Market

29.1. Africa Intravenous Iron Drugs Market Overview
29.2. Africa Intravenous Iron Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Intravenous Iron Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Intravenous Iron Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intravenous Iron Drugs Market Competitive Landscape And Company Profiles

30.1. Intravenous Iron Drugs Market Competitive Landscape
30.2. Intravenous Iron Drugs Market Company Profiles
- 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Intravenous Iron Drugs Market Other Major And Innovative Companies

31.1. CSL Limited
31.2. Sandoz Group AG.
31.3. Daiichi Sankyo Company Ltd.
31.4. Sun Pharmaceutical Industries Ltd.
31.5. Galenica Ltd.
31.6. Dr.Reddy's Laboratories
31.7. Hikma Pharmaceuticals plc
31.8. Zydus Lifesciences Limited
31.9. Biocon Limited
31.10. Kissei Pharmaceutical Co. Ltd.
31.11. American Regent Inc.
31.12. Akebia Therapeutics Inc.
31.13. Rockwell Medical Inc.
31.14. Pharmacosmos A/S
31.15. Shield Therapeutics plc

32. Global Intravenous Iron Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intravenous Iron Drugs Market

34. Recent Developments In The Intravenous Iron Drugs Market

35. Intravenous Iron Drugs Market High Potential Countries, Segments and Strategies

35.1 Intravenous Iron Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Intravenous Iron Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Intravenous Iron Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34882_Intravenous_Iron_Drugs_GMR_2025